786 related articles for article (PubMed ID: 27493272)
1. Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results.
Nock BA; Kaloudi A; Lymperis E; Giarika A; Kulkarni HR; Klette I; Singh A; Krenning EP; de Jong M; Maina T; Baum RP
J Nucl Med; 2017 Jan; 58(1):75-80. PubMed ID: 27493272
[TBL] [Abstract][Full Text] [Related]
2. 68Ga/177Lu-NeoBOMB1, a Novel Radiolabeled GRPR Antagonist for Theranostic Use in Oncology.
Dalm SU; Bakker IL; de Blois E; Doeswijk GN; Konijnenberg MW; Orlandi F; Barbato D; Tedesco M; Maina T; Nock BA; de Jong M
J Nucl Med; 2017 Feb; 58(2):293-299. PubMed ID: 27609789
[TBL] [Abstract][Full Text] [Related]
3. Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [⁶⁸Ga]SB3 and PET/CT.
Maina T; Bergsma H; Kulkarni HR; Mueller D; Charalambidis D; Krenning EP; Nock BA; de Jong M; Baum RP
Eur J Nucl Med Mol Imaging; 2016 May; 43(5):964-973. PubMed ID: 26631238
[TBL] [Abstract][Full Text] [Related]
4. Preclinical comparison of Al18F- and 68Ga-labeled gastrin-releasing peptide receptor antagonists for PET imaging of prostate cancer.
Chatalic KL; Franssen GM; van Weerden WM; McBride WJ; Laverman P; de Blois E; Hajjaj B; Brunel L; Goldenberg DM; Fehrentz JA; Martinez J; Boerman OC; de Jong M
J Nucl Med; 2014 Dec; 55(12):2050-6. PubMed ID: 25413139
[TBL] [Abstract][Full Text] [Related]
5. Radiometal-Dependent Biological Profile of the Radiolabeled Gastrin-Releasing Peptide Receptor Antagonist SB3 in Cancer Theranostics: Metabolic and Biodistribution Patterns Defined by Neprilysin.
Lymperis E; Kaloudi A; Sallegger W; Bakker IL; Krenning EP; de Jong M; Maina T; Nock BA
Bioconjug Chem; 2018 May; 29(5):1774-1784. PubMed ID: 29664606
[TBL] [Abstract][Full Text] [Related]
6. Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor Antagonist.
Zhang H; Desai P; Koike Y; Houghton J; Carlin S; Tandon N; Touijer K; Weber WA
J Nucl Med; 2017 Jan; 58(1):29-35. PubMed ID: 27516447
[TBL] [Abstract][Full Text] [Related]
7. NeoBOMB1, a GRPR-Antagonist for Breast Cancer Theragnostics: First Results of a Preclinical Study with [
Kaloudi A; Lymperis E; Giarika A; Dalm S; Orlandi F; Barbato D; Tedesco M; Maina T; de Jong M; Nock BA
Molecules; 2017 Nov; 22(11):. PubMed ID: 29137110
[TBL] [Abstract][Full Text] [Related]
8. Substitution of l-Tryptophan by
Günther T; Deiser S; Felber V; Beck R; Wester HJ
J Nucl Med; 2022 Sep; 63(9):1364-1370. PubMed ID: 35027371
[TBL] [Abstract][Full Text] [Related]
9. Positron Emission Tomography Imaging of the Gastrin-Releasing Peptide Receptor with a Novel Bombesin Analogue.
Lau J; Rousseau E; Zhang Z; Uribe CF; Kuo HT; Zeisler J; Zhang C; Kwon D; Lin KS; Bénard F
ACS Omega; 2019 Jan; 4(1):1470-1478. PubMed ID: 30775647
[TBL] [Abstract][Full Text] [Related]
10. Comparison of biological properties of [
Rousseau E; Lau J; Zhang Z; Zhang C; Kwon D; Uribe CF; Kuo HT; Zeisler J; Bratanovic I; Lin KS; Bénard F
J Labelled Comp Radiopharm; 2020 Feb; 63(2):56-64. PubMed ID: 31715025
[TBL] [Abstract][Full Text] [Related]
11. Biological evaluation of (177)Lu-labeled DOTA-Ala(SO3H)-Aminooctanoyl-Gln-Trp-Ala-Val-N methyl Gly-His-Statine-Leu-NH2 for gastrin-releasing peptide receptor-positive prostate tumor targeting.
Lim JC; Cho EH; Kim JJ; Choi SM; Lee Sy; Nam SS; Park UJ; Park SH
Nucl Med Biol; 2015 Feb; 42(2):131-6. PubMed ID: 25457455
[TBL] [Abstract][Full Text] [Related]
12. N-terminal modifications improve the receptor affinity and pharmacokinetics of radiolabeled peptidic gastrin-releasing peptide receptor antagonists: examples of 68Ga- and 64Cu-labeled peptides for PET imaging.
Gourni E; Mansi R; Jamous M; Waser B; Smerling C; Burian A; Buchegger F; Reubi JC; Maecke HR
J Nucl Med; 2014 Oct; 55(10):1719-25. PubMed ID: 25146125
[TBL] [Abstract][Full Text] [Related]
13. 99mTc radiotracers based on human GRP(18-27): synthesis and comparative evaluation.
Marsouvanidis PJ; Maina T; Sallegger W; Krenning EP; de Jong M; Nock BA
J Nucl Med; 2013 Oct; 54(10):1797-803. PubMed ID: 24009275
[TBL] [Abstract][Full Text] [Related]
14. A Radiotracer for Molecular Imaging and Therapy of Gastrin-Releasing Peptide Receptor-Positive Prostate Cancer.
Bratanovic IJ; Zhang C; Zhang Z; Kuo HT; Colpo N; Zeisler J; Merkens H; Uribe C; Lin KS; Bénard F
J Nucl Med; 2022 Mar; 63(3):424-430. PubMed ID: 34301778
[TBL] [Abstract][Full Text] [Related]
15. A new (68)Ga-labeled BBN peptide with a hydrophilic linker for GRPR-targeted tumor imaging.
Pan D; Xu YP; Yang RH; Wang L; Chen F; Luo S; Yang M; Yan Y
Amino Acids; 2014 Jun; 46(6):1481-9. PubMed ID: 24633452
[TBL] [Abstract][Full Text] [Related]
16. Characterization and evaluation of DOTA-conjugated Bombesin/RGD-antagonists for prostate cancer tumor imaging and therapy.
Stott Reynolds TJ; Schehr R; Liu D; Xu J; Miao Y; Hoffman TJ; Rold TL; Lewis MR; Smith CJ
Nucl Med Biol; 2015 Feb; 42(2):99-108. PubMed ID: 25459113
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and characterization of a high-affinity NOTA-conjugated bombesin antagonist for GRPR-targeted tumor imaging.
Varasteh Z; Velikyan I; Lindeberg G; Sörensen J; Larhed M; Sandström M; Selvaraju RK; Malmberg J; Tolmachev V; Orlova A
Bioconjug Chem; 2013 Jul; 24(7):1144-53. PubMed ID: 23763444
[TBL] [Abstract][Full Text] [Related]
18. Preclinical pharmacokinetic, biodistribution, imaging and therapeutic efficacy of (177)Lu-Labeled glycated bombesin analogue for gastrin-releasing peptide receptor-positive prostate tumor targeting.
Lim JC; Cho EH; Kim JJ; Choi SM; Lee SY; Nam SS; Park UJ; Park SH
Nucl Med Biol; 2015 Mar; 42(3):234-41. PubMed ID: 25498002
[TBL] [Abstract][Full Text] [Related]
19. Bombesin antagonist-based radioligands for translational nuclear imaging of gastrin-releasing peptide receptor-positive tumors.
Abiraj K; Mansi R; Tamma ML; Fani M; Forrer F; Nicolas G; Cescato R; Reubi JC; Maecke HR
J Nucl Med; 2011 Dec; 52(12):1970-8. PubMed ID: 22080443
[TBL] [Abstract][Full Text] [Related]
20. Preclinical Comparison of the
Koller L; Joksch M; Schwarzenböck S; Kurth J; Heuschkel M; Holzleitner N; Beck R; von Amsberg G; Wester HJ; Krause BJ; Günther T
J Nucl Med; 2023 Oct; 64(10):1654-1659. PubMed ID: 37934025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]